Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04678037 · ClinicalTrials.gov registry record · NA

Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study

A NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT04678037: Completed NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

NCT04678037 is a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 40 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04678037, a NA study of Sickle Cell Disease and Sickle Beta Zero Thalassemia, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The overarching goal of this proposal is to identify modifiable behavioral strategies based on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) that will improve hydroxyurea (HU) adherence among adolescents and young adults with sickle cell disease (SCD). In this proposed study, we intend to test the functionality of a PROs-toolbox feature, which will be integrated into our existing smartphone application platform (SCD-app), over a 24-week period in a cohort of SCD patients and their caregivers.

Primary Outcome

Having an overall completion rate of ≥ 50% for all study participants (Group A and B). This will be reported as a dichotomous outcome, either yes or no. The percentage (%) completion rate will be calculated as the number of PROs assessments completed divided by the number of PROs assessments expected over the study period.

Conditions Studied

Sickle Cell Disease Sickle Beta Zero Thalassemia Sickle B+ Thalassemia Sickle Cell Hemoglobin C

Interventions

  • BEHAVIORAL PROs assessment using sickle cell disease mobile app (SCD-app)

Study Locations (1)

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-04-04
Est. Completion 2019-07-21
Phase NA
Ann & Robert H Lurie Children's Hospital of Chicago

159 total trials

What the finished NCT04678037 record still lists

NCT04678037 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (86% lower).

The record links to 4 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which PROs assessment using sickle cell disease mobile app (SCD-app) is the first listed.

NCT04678037 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT04678037 about?

NCT04678037 is a clinical study titled "Home-based Assessment of PRO Measures in SCD Using A Smartphone App Platform: A Feasibility Study". The overarching goal of this proposal is to identify modifiable behavioral strategies based on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) that will improve hydroxyurea (HU) adherence among adolescents and young adults with sickle cell disease (SCD). In this proposed ...

What is the current status of trial NCT04678037?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2017-04-04. Estimated completion is 2019-07-21.

What conditions does trial NCT04678037 study?

This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Beta Zero Thalassemia, Sickle B+ Thalassemia, Sickle Cell Hemoglobin C.

What interventions are being tested in trial NCT04678037?

The interventions under investigation include: PROs assessment using sickle cell disease mobile app (SCD-app) (BEHAVIORAL).

Who is sponsoring clinical trial NCT04678037?

This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04678037 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04678037's enrollment target sits among peer trials

40 124th of 213 higher than 86 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04678037, the US trial registry maintained by the National Library of Medicine. NCT04678037 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.